View Older Stories

Apr 23, 2026 07:00AM Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Apr 13, 2026 07:00AM Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

Apr 9, 2026 07:00AM Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

Mar 30, 2026 07:18AM Phio Pharmaceuticals signs manufacturing agreement for cancer drug

Mar 30, 2026 07:00AM Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

Mar 23, 2026 07:02AM Phio Pharmaceuticals to present PH-762 cancer study results at dermatology meeting

Mar 23, 2026 07:00AM Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancemen

Mar 16, 2026 11:30AM Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office

Mar 10, 2026 07:00AM Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

Mar 5, 2026 04:05PM Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

Mar 5, 2026 07:00AM Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Feb 19, 2026 07:00AM Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894

Feb 10, 2026 07:06AM Phio reports positive safety data for PH-762 skin cancer treatment

Feb 10, 2026 07:00AM Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Jan 26, 2026 08:15AM Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

Jan 23, 2026 02:50PM DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event

Jan 23, 2026 02:50PM DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event

Jan 23, 2026 02:50PM DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event

Jan 23, 2026 02:50PM DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event

Jan 20, 2026 09:32AM Phio Pharmaceuticals reports 70% response rate in skin cancer trial

Jan 20, 2026 09:30AM Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Jan 15, 2026 08:45AM Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Dec 23, 2025 08:47AM Phio Pharmaceuticals receives FDA acceptance for PH-762 toxicology study

Dec 23, 2025 08:45AM Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nov 25, 2025 11:32AM Phio Pharmaceuticals completes enrollment in Phase 1b trial for PH-762

Nov 25, 2025 11:30AM Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Nov 20, 2025 04:08PM Phio Pharmaceuticals Corp. (PHIO) files for 11.76M share offering by selling stockholders

Nov 17, 2025 08:45AM Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 13, 2025 06:33PM Phio Pharmaceuticals Corp. (PHIO) Misses Q3 EPS by 44c

Nov 13, 2025 04:15PM Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025 10:30AM Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025 07:47AM Phio Pharmaceuticals' PH-762 wins biotech breakthrough award

Nov 7, 2025 07:45AM Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 3, 2025 01:42PM Phio Pharmaceuticals raises $13.4 million through warrant exercises

Nov 3, 2025 01:40PM Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025 07:48AM Phio Pharmaceuticals reports positive results in skin cancer trial

Nov 3, 2025 07:45AM Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Oct 31, 2025 10:19AM Phio Pharmaceuticals names David Deming as lead independent director

Oct 31, 2025 10:15AM Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 21, 2025 07:45AM Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Sep 23, 2025 07:45AM Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Sep 18, 2025 07:45AM Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 3, 2025 07:45AM Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 15, 2025 06:09AM Phio Pharmaceuticals Corp. (PHIO) Files for 1.93M Share Offering by Selling Stockholders

Aug 14, 2025 05:25PM Phio Pharmaceuticals Corp. (PHIO) Misses Q2 EPS by 45c

Aug 14, 2025 04:15PM Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025 03:08PM Phio Pharmaceuticals raises $2.5 million through warrant exercise

Jul 25, 2025 03:04PM Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025 12:46PM Phio Pharmaceuticals reports complete response in skin cancer trial

Jul 25, 2025 12:36PM Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

View Older Stories